17β-Estradiol improves osteoblastic cell function through the Sirt1/NF-κB/MMP-8 pathway

Area of Science:

• Endocrinology
• Cell Biology
• Bone Biology

Background:

• Postmenopausal osteoporosis is a significant health concern.
• Estrogen deficiency negatively impacts osteoblast function.
• Identifying pathways that mediate estrogen's protective effects on bone is crucial.

Purpose of the Study:

• To investigate the role of 17β-estradiol in modulating osteoblastic cell function.
• To elucidate the involvement of the Sirtuin-1/nuclear transcription factor-κB/matrix metalloproteinase-8 (Sirt1/NF-κB/MMP-8) pathway in 17β-estradiol's effects.
• To assess the potential of 17β-estradiol as a therapeutic agent for osteoporosis.

Main Methods:

• Primary mouse osteoblasts were cultured and treated with 17β-estradiol.
• Expression levels of estrogen receptor-α (ERα), Sirt1, NF-κB, and MMP-8 were analyzed.
• Sirt1 was knocked down to confirm its role in mediating 17β-estradiol's effects.
• Osteoblast function and bone formation biomarkers were assessed.

Main Results:

• 17β-estradiol treatment improved osteoblastic cell viability and increased bone formation markers (osteocalcin, OPG, P1NP, ALP).
• 17β-estradiol upregulated ERα and Sirt1 expression while downregulating NF-κB and MMP-8.
• Knockdown of Sirt1 abolished the beneficial effects of 17β-estradiol on osteoblast function and signaling pathway modulation.

Conclusions:

• 17β-estradiol enhances osteoblastic cell function through the Sirt1/NF-κB/MMP-8 pathway.
• This pathway is critical for mediating the bone-protective effects of 17β-estradiol.
• 17β-estradiol replacement therapy holds promise for treating postmenopausal osteoporosis.